Survival prospects of pulmonary arterial hypertension associated with congenital heart disease: Insights from the HOPE registry

Survival prospects were favorable for the non-high risk patients in this nationwide cohort of PAH-ACHD patients. The observed shift towards combination therapy use may have contributed to the improvement in 1-year ESC mortality risk, underscoring the importance of timely combination therapy with PAH drugs.